Developer docs
API playgroundTry for free, no card

Search company profiles

Stablepharma Ltd

Full company profile

uuid00023hi

Namestring
Stablepharma Ltd
Legal namestring
Stablepharma Limited
Company typeenum
Private
Founded yearint
2012
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBath, United Kingdom
HQ citystring
Bath
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
thermostable vaccines, vaccine reformulation platform, cold chain elimination, trehalose stabilization technology, biopharmaceutical licensing
Industry4 codes
PRIMARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAK
Vaccine Cold Chain, Storage & Distribution
SECONDARYHLAAAEAJ
Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Thermostable Vaccines and Biopharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Development and option-to-license agreements generating milestone payments as products advance through development stages. Revenue flows upon achievement of pre-defined development, regulatory, and commercialization milestones.

biospace.com
2Royalty Revenue
TypeLicensing Royalties
Description

Royalty payments upon commercialization of licensed products. AFT Pharmaceuticals partnership includes milestone and royalty revenue upon commercialisation of anti-infective and oncology injectables.

biospace.com
3Government Grants
TypeManaged Services
Description

Funding from Innovate UK Smart Grants and EIC Accelerator Grant to support clinical development of fridge-free vaccine candidates, particularly SPVX02 for tetanus and diphtheria.

stablepharma.com
4Vaccine Product Sales
TypeOne Time License
Description

Future revenue from direct sales and distribution of fridge-free vaccines. Stablepharma will own global marketing authorisation for SPVX02 and SPVX06 vaccines and be responsible for registration and sales.

stablepharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Stablepharma develops and licenses its proprietary StablevaX™ thermostabilization platform, which reformulates existing approved vaccines and pharmaceuticals into fridge-free products stable at 40°C and above using trehalose-based stabilization. Its lead candidates are SPVX02 (fridge-free tetanus-diphtheria adult booster vaccine, currently in Phase 1 clinical trials with database lock in November 2025) and SPVX06 (fridge-free tetanus toxoid vaccine), along with an mRNA-LNP thermostabilization programme. The company generates revenue through B2B development and licensing agreements, milestone payments, royalties, and government grants.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Vaccines stable at 45°C for 12+ months without potency loss, exceeding WHO requirements of 6 months at 40°C
+4 more records
Product overview1 text field

Stablepharma Ltd is a UK-based biotech company developing a portfolio of fridge-free vaccines and pharmaceuticals using its proprietary StablevaX™ technology platform. The core offering centers on SPVX02, the world's first fridge-free tetanus-diphtheria vaccine currently in Phase 1 clinical trials, and SPVX06, a fridge-free tetanus vaccine. The StablevaX™ platform enables the reformulation of existing approved vaccines and pharmaceuticals into thermostable products that remain stable without refrigeration at temperatures up to 40°C and above. The company is also advancing an mRNA-LNP thermostabilization programme in partnership with the University of Strathclyde, and has expanded into anti-infective and oncology sterile injectables through a partnership with AFT Pharmaceuticals.

Product and service4 records
1StablevaX™
CategoryThermostable biopharmaceutical platform
Description

Proprietary thermostabilization technology platform that reformulates existing approved vaccines and pharmaceuticals into fridge-free forms stable at temperatures of 40°C and above, using trehalose-based stabilization to eliminate cold-chain requirements. Licensed to and co-developed with pharmaceutical partners.

2SPVX02
CategoryThermostable vaccine
Description

The world's first fridge-free tetanus-diphtheria (Td) adult booster vaccine, developed using the StablevaX™ technology platform with bulk antigen supply from BB-NCIPD Ltd (Bul Bio). Currently in Phase 1 clinical trials in the UK, with database lock announced in November 2025 and Phase 2/3 trials in preparation.

3SPVX06
CategoryThermostable vaccine
Description

A fridge-free Tetanus Toxoid (TT) vaccine reformulated using StablevaX™ technology from Tetatox vaccine manufactured by Bulbio Ltd (BB-NCIPD). Demonstrated 12-month stability at +40°C/75%RH with full protection and sustained immunogenicity in in-vivo challenge studies.

4StablevaX™-mRNA-LNP Programme
CategoryThermostable mRNA-LNP technology
Description

Research and development programme focused on thermostabilizing mRNA-LNP vaccines (such as COVID-19 vaccines) using the StablevaX™ platform, including naked mRNA kept stable at 45°C for extended periods. Conducted in partnership with the University of Strathclyde, leveraging world-class lipid nanoparticle manufacturing expertise.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-15
Description

Development and option-to-license agreement to develop fridge-free sterile injectable medicines targeting anti-infective and oncology treatments in a global market valued at over USD 6 billion. Stablepharma applies StablevaX™ stabilization technology to non-vaccine injectables currently requiring cold-chain storage. Milestone and royalty revenue flows to Stablepharma upon commercialisation. Strategic expansion beyond vaccines enabling both companies to broaden their portfolio of thermostable products.

Strategic tierSignificantTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-12-11
Description

Strategic Letter of Intent to distribute and commercialise fridge-free vaccines across Europe. Partnership announced December 2024 for European market distribution of SPVX02.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-01
Description

World-leading sterile manufacturing CDMO partnership. Successfully manufactured and tested 10,000+ vials of SPVX02 under GMP conditions in Monza, Italy. PPD managing Phase 2/3 pivotal trial across approximately 10 sites in UK and Spain. Manufacturing licence approved by AIFA (Italian Regulatory Agency).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-01
Description

Clinical development partnership for SPVX02 Phase 1 clinical trial led by Professor Saul Faust OBE. Joint Innovate UK grant to advance clinical development, validating safety and efficacy through first-in-human trials. NIHR Southampton Clinical Research Facility serves as primary trial site.

5BB-NCIPD Ltd (Bul Bio)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-20
Description

Bulgarian state-owned vaccine manufacturer (Ministry of Health) with GMP facilities exporting to 100+ countries. Exclusive bulk supply and commercialisation agreement for Tetanus diphtheria vaccine (SPVX02) and Tetanus mono vaccine (SPVX06). Bul Bio supplies bulk vaccine and shares regulatory dossiers; Stablepharma has exclusive rights to manufacture and distribute StablevaX™-Td globally and owns global marketing authorisation. Bul Bio has first right of refusal for Balkans territories and NGOs. One of five WHO pre-qualified Td vaccine suppliers, supplying approximately 9% of global demand.

stablepharma.com
6University of Strathclyde
Strategic tierCoreTypeStrategic or Co-development Partner
Description

R&D partnership for COVID-19 mRNA vaccine thermo-stabilisation technology. University team provides world-class manufacturing expertise for lipid nanoparticles (LNPs). Collaboration aims to create thermostable mRNA/LNP vaccine analogues similar to vaccines on the market.

stablepharma.com
Strategic tierSupportingTypeImplementation/ SI/ Consulting Partner
Description

Regulatory consulting partner pursuing regulatory requirements for reformulated tetanus diphtheria vaccine (SPVX02). Prof. Alan Boyd serves on Stablepharma Advisory Board.

Strategic tierSupportingTypeTechnology or Integration
Description

UK's national institute for biological standards. Collaboration on ELISA assay development validating toxoid integrity for Stability testing.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Vaxess Technologies
TypeDirect peer
Description

US-based biotech developing a sustained-release vaccine patch platform (including mRNA and flu vaccines) aimed at eliminating cold-chain storage and enabling fridge-stable delivery. Directly comparable to Stablepharma as a vaccine thermostabilization/delivery platform targeting similar LMIC and global public-health customers.

TypeDirect peer
Description

Clinical-stage developer of dissolvable microneedle array patches for vaccines and therapeutics, designed to remove cold-chain dependency and enable self-administration. Highly comparable product format and value proposition to StablevaX™-enabled fridge-free delivery.

TypeEmerging player
Description

Maker of needle-free injection devices (Tropis and Stratis) used for vaccine and therapeutic delivery, including WHO-prequalified needle-free polio immunization campaigns. Comparable as an alternative cold-chain-reducing delivery technology targeting LMIC public-health buyers.

TypeBroad incumbent
Description

Global specialty chemicals company whose life sciences arm supplies vaccine adjuvants, excipients and lipid systems (including for mRNA/LNP formulations). Comparable as an established supplier into vaccine formulation, though far broader than Stablepharma's single thermostable platform.

TypeBroad incumbent
Description

mRNA vaccine leader whose Pfizer-partnered COVID-19 vaccine requires ultra-cold storage at -70°C—precisely the cold-chain problem Stablepharma's StablevaX™-mRNA-LNP programme aims to solve. Comparable as the dominant incumbent whose product format Stablepharma seeks to reformulate.

TypeBroad incumbent
Description

Major Indian vaccine manufacturer with a broad WHO-prequalified portfolio (rotavirus, typhoid, Td, etc.) where StablevaX™ reformulation could add thermostable versions. Comparable as an emerging-market vaccine manufacturer and a likely licensing/customer target for Stablepharma.

7BB-NCIPD (Bul Bio)
TypeRegional player
Description

Bulgarian state-owned vaccine manufacturer and Stablepharma's exclusive bulk supplier for SPVX02/SPVX06, exporting to 100+ countries and supplying ~9% of global Td vaccine demand. Comparable as a regional vaccine manufacturer partnering with Stablepharma, and a potential competitor if it in-houses stabilization.

8Exothera
TypeEmerging player
Description

Belgian viral vector and biologics CDMO specializing in process development and GMP manufacturing for vaccines and gene therapies, with public-health mission overlap. Comparable as a scale-up CDMO serving the same LMIC and global health customer base Stablepharma targets.

TypeRegional player
Description

Scandinavian vaccine manufacturer (tetanus, diphtheria, BCG, travel vaccines) and Stablepharma's European distribution channel partner. Comparable as a regional vaccine manufacturer whose product portfolio is a candidate for StablevaX™ reformulation and which could emerge as a competitor.

TypeEmerging player
Description

US-based essential medicines CDMO focused on domestically manufactured active pharmaceutical ingredients and finished sterile injectables, with HHS/ASPR partnerships. Comparable as a public-health-mission drug manufacturer with overlap into sterile injectables, the same adjacency Stablepharma entered via the AFT partnership.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles23 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stablepharma Ltd

Thermostable Vaccines and Biopharmaceuticalsstablepharma.com

Stablepharma Ltd firmographics

Firmographics
Name
Stablepharma Ltd
Legal name
Stablepharma Limited
Website
https://stablepharma.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Stablepharma Ltd industry classification

Industry
Product category
Thermostable Vaccines and Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAK
Vaccine Cold Chain, Storage & Distribution
SECONDARYHLAAAEAJ
Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Thermostable vaccines
  • Vaccine reformulation platform
  • Cold chain elimination
  • Trehalose stabilization technology
  • Biopharmaceutical licensing

Where Stablepharma Ltd is headquartered

Location

Headquarters

HQ city
Bath
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Stablepharma Ltd business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing and Milestone Payments: Development and option-to-license agreements generating milestone payments as products advance through development stages. Revenue flows upon achievement of pre-defined development, regulatory, and commercialization milestones.
  2. Royalty Revenue: Royalty payments upon commercialization of licensed products. AFT Pharmaceuticals partnership includes milestone and royalty revenue upon commercialisation of anti-infective and oncology injectables.
  3. Government Grants: Funding from Innovate UK Smart Grants and EIC Accelerator Grant to support clinical development of fridge-free vaccine candidates, particularly SPVX02 for tetanus and diphtheria.
  4. Vaccine Product Sales: Future revenue from direct sales and distribution of fridge-free vaccines. Stablepharma will own global marketing authorisation for SPVX02 and SPVX06 vaccines and be responsible for registration and sales.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Stablepharma Ltd product offering

Product offering

Core offering

Stablepharma develops and licenses its proprietary StablevaX™ thermostabilization platform, which reformulates existing approved vaccines and pharmaceuticals into fridge-free products stable at 40°C and above using trehalose-based stabilization. Its lead candidates are SPVX02 (fridge-free tetanus-diphtheria adult booster vaccine, currently in Phase 1 clinical trials with database lock in November 2025) and SPVX06 (fridge-free tetanus toxoid vaccine), along with an mRNA-LNP thermostabilization programme. The company generates revenue through B2B development and licensing agreements, milestone payments, royalties, and government grants.

Product overview

Stablepharma Ltd is a UK-based biotech company developing a portfolio of fridge-free vaccines and pharmaceuticals using its proprietary StablevaX™ technology platform. The core offering centers on SPVX02, the world's first fridge-free tetanus-diphtheria vaccine currently in Phase 1 clinical trials, and SPVX06, a fridge-free tetanus vaccine. The StablevaX™ platform enables the reformulation of existing approved vaccines and pharmaceuticals into thermostable products that remain stable without refrigeration at temperatures up to 40°C and above. The company is also advancing an mRNA-LNP thermostabilization programme in partnership with the University of Strathclyde, and has expanded into anti-infective and oncology sterile injectables through a partnership with AFT Pharmaceuticals.

Differentiator

Problem solved

Functional benefit

Products and services

  • StablevaX™ Proprietary thermostabilization technology platform that reformulates existing approved vaccines and pharmaceuticals into fridge-free forms stable at temperatures of 40°C and above, using trehalose-based stabilization to eliminate cold-chain requirements. Licensed to and co-developed with pharmaceutical partners.
  • SPVX02 The world's first fridge-free tetanus-diphtheria (Td) adult booster vaccine, developed using the StablevaX™ technology platform with bulk antigen supply from BB-NCIPD Ltd (Bul Bio). Currently in Phase 1 clinical trials in the UK, with database lock announced in November 2025 and Phase 2/3 trials in preparation.
  • SPVX06 A fridge-free Tetanus Toxoid (TT) vaccine reformulated using StablevaX™ technology from Tetatox vaccine manufactured by Bulbio Ltd (BB-NCIPD). Demonstrated 12-month stability at +40°C/75%RH with full protection and sustained immunogenicity in in-vivo challenge studies.
  • StablevaX™-mRNA-LNP Programme Research and development programme focused on thermostabilizing mRNA-LNP vaccines (such as COVID-19 vaccines) using the StablevaX™ platform, including naked mRNA kept stable at 45°C for extended periods. Conducted in partnership with the University of Strathclyde, leveraging world-class lipid nanoparticle manufacturing expertise.

Quantifiable outcome

  • Vaccines stable at 45°C for 12+ months without potency loss, exceeding WHO requirements of 6 months at 40°C
  • +4 more outcomes

Companies that use Stablepharma Ltd

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Stablepharma Ltd technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Stablepharma Ltd partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, significant and supporting.

  • AFT Pharmaceuticals (NZX: AFT; ASX: AFP)coreStrategic or Co-development Partner · 15 January 2026Development and option-to-license agreement to develop fridge-free sterile injectable medicines targeting anti-infective and oncology treatments in a global market valued at over USD 6 billion. Stablepharma applies StablevaX™ stabilization technology to non-vaccine injectables currently requiring cold-chain storage. Milestone and royalty revenue flows to Stablepharma upon commercialisation. Strategic expansion beyond vaccines enabling both companies to broaden their portfolio of thermostable products.
  • AJ VaccinessignificantChannel Partner/ Reseller/ Distributor · 11 December 2024Strategic Letter of Intent to distribute and commercialise fridge-free vaccines across Europe. Partnership announced December 2024 for European market distribution of SPVX02.
  • Thermo Fisher Scientific (PPD)coreStrategic or Co-development Partner · 1 June 2024World-leading sterile manufacturing CDMO partnership. Successfully manufactured and tested 10,000+ vials of SPVX02 under GMP conditions in Monza, Italy. PPD managing Phase 2/3 pivotal trial across approximately 10 sites in UK and Spain. Manufacturing licence approved by AIFA (Italian Regulatory Agency).
  • University Hospital Southampton NHS Foundation TrustcoreStrategic or Co-development Partner · 1 September 2023Clinical development partnership for SPVX02 Phase 1 clinical trial led by Professor Saul Faust OBE. Joint Innovate UK grant to advance clinical development, validating safety and efficacy through first-in-human trials. NIHR Southampton Clinical Research Facility serves as primary trial site.
  • BB-NCIPD Ltd (Bul Bio)coreStrategic or Co-development Partner · 20 September 2022Bulgarian state-owned vaccine manufacturer (Ministry of Health) with GMP facilities exporting to 100+ countries. Exclusive bulk supply and commercialisation agreement for Tetanus diphtheria vaccine (SPVX02) and Tetanus mono vaccine (SPVX06). Bul Bio supplies bulk vaccine and shares regulatory dossiers; Stablepharma has exclusive rights to manufacture and distribute StablevaX™-Td globally and owns global marketing authorisation. Bul Bio has first right of refusal for Balkans territories and NGOs. One of five WHO pre-qualified Td vaccine suppliers, supplying approximately 9% of global demand.
  • University of StrathclydecoreStrategic or Co-development PartnerR&D partnership for COVID-19 mRNA vaccine thermo-stabilisation technology. University team provides world-class manufacturing expertise for lipid nanoparticles (LNPs). Collaboration aims to create thermostable mRNA/LNP vaccine analogues similar to vaccines on the market.
  • Boyds ConsultantssupportingImplementation/ SI/ Consulting PartnerRegulatory consulting partner pursuing regulatory requirements for reformulated tetanus diphtheria vaccine (SPVX02). Prof. Alan Boyd serves on Stablepharma Advisory Board.
  • NIBSC (National Institute for Biological Standards and Control)supportingTechnology or IntegrationUK's national institute for biological standards. Collaboration on ELISA assay development validating toxoid integrity for Stability testing.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

Stablepharma Ltd competitors and assessment

Company assessment

Direct peers

  • Vaxess Technologies: US-based biotech developing a sustained-release vaccine patch platform (including mRNA and flu vaccines) aimed at eliminating cold-chain storage and enabling fridge-stable delivery. Directly comparable to Stablepharma as a vaccine thermostabilization/delivery platform targeting similar LMIC and global public-health customers.
  • Micron Biomedical: Clinical-stage developer of dissolvable microneedle array patches for vaccines and therapeutics, designed to remove cold-chain dependency and enable self-administration. Highly comparable product format and value proposition to StablevaX™-enabled fridge-free delivery.

Emerging players

  • PharmaJet: Maker of needle-free injection devices (Tropis and Stratis) used for vaccine and therapeutic delivery, including WHO-prequalified needle-free polio immunization campaigns. Comparable as an alternative cold-chain-reducing delivery technology targeting LMIC public-health buyers.
  • Exothera: Belgian viral vector and biologics CDMO specializing in process development and GMP manufacturing for vaccines and gene therapies, with public-health mission overlap. Comparable as a scale-up CDMO serving the same LMIC and global health customer base Stablepharma targets.
  • Phlow Corp: US-based essential medicines CDMO focused on domestically manufactured active pharmaceutical ingredients and finished sterile injectables, with HHS/ASPR partnerships. Comparable as a public-health-mission drug manufacturer with overlap into sterile injectables, the same adjacency Stablepharma entered via the AFT partnership.

Broad incumbents

  • Croda International: Global specialty chemicals company whose life sciences arm supplies vaccine adjuvants, excipients and lipid systems (including for mRNA/LNP formulations). Comparable as an established supplier into vaccine formulation, though far broader than Stablepharma's single thermostable platform.
  • BioNTech: mRNA vaccine leader whose Pfizer-partnered COVID-19 vaccine requires ultra-cold storage at -70°C—precisely the cold-chain problem Stablepharma's StablevaX™-mRNA-LNP programme aims to solve. Comparable as the dominant incumbent whose product format Stablepharma seeks to reformulate.
  • Bharat Biotech: Major Indian vaccine manufacturer with a broad WHO-prequalified portfolio (rotavirus, typhoid, Td, etc.) where StablevaX™ reformulation could add thermostable versions. Comparable as an emerging-market vaccine manufacturer and a likely licensing/customer target for Stablepharma.

Regional players

  • BB-NCIPD (Bul Bio): Bulgarian state-owned vaccine manufacturer and Stablepharma's exclusive bulk supplier for SPVX02/SPVX06, exporting to 100+ countries and supplying ~9% of global Td vaccine demand. Comparable as a regional vaccine manufacturer partnering with Stablepharma, and a potential competitor if it in-houses stabilization.
  • AJ Vaccines: Scandinavian vaccine manufacturer (tetanus, diphtheria, BCG, travel vaccines) and Stablepharma's European distribution channel partner. Comparable as a regional vaccine manufacturer whose product portfolio is a candidate for StablevaX™ reformulation and which could emerge as a competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Stablepharma Ltd social profiles

Digital presence

Stablepharma Ltd compliance and trust

Trust signal

Compliance1 record

Stablepharma Ltd financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stablepharma Ltd leadership team

Management profile

Number of profiles

Profiles23 records

Stablepharma Ltd subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Stablepharma Ltd funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stablepharma Ltd M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stablepharma Ltd

What does Stablepharma Ltd do?

Stablepharma develops and licenses its proprietary StablevaX™ thermostabilization platform, which reformulates existing approved vaccines and pharmaceuticals into fridge-free products stable at 40°C and above using trehalose-based stabilization. Its lead candidates are SPVX02 (fridge-free tetanus-diphtheria adult booster vaccine, currently in Phase 1 clinical trials with database lock in November 2025) and SPVX06 (fridge-free tetanus toxoid vaccine), along with an mRNA-LNP thermostabilization programme. The company generates revenue through B2B development and licensing agreements, milestone payments, royalties, and government grants.

Is Stablepharma Ltd a public or private company?

Stablepharma Ltd is a private company. It is classified as venture growth investor backed and is currently operating.

When was Stablepharma Ltd founded?

Stablepharma Ltd was founded in 2012. It employs 11 to 50 people.

Where is Stablepharma Ltd based?

Stablepharma Ltd is headquartered in Bath, United Kingdom, in the Europe region.

How does Stablepharma Ltd make money?

Four revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are royalty Revenue, government Grants and vaccine Product Sales.

Who are Stablepharma Ltd's main competitors?

Direct peers on record are Vaxess Technologies and Micron Biomedical. Emerging players are PharmaJet, Exothera and Phlow Corp. Broad incumbents are Croda International, BioNTech and Bharat Biotech. Regional players are BB-NCIPD (Bul Bio) and AJ Vaccines.

Does Stablepharma Ltd have an API?

No public API is recorded for Stablepharma Ltd.

What industry is Stablepharma Ltd in?

Stablepharma Ltd's product category is Thermostable Vaccines and Biopharmaceuticals. Its primary akta.pro industry code is HLAAAEAK, Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release), with a secondary code of HLAAAEAA, Prophylactic Human Vaccines (routine, pediatric, adult). Its NAICS code is 325412 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireFridge-free vaccines could reach more people, but there are still practical challenges in African settingsStablepharma began the first human trial of a fridge-free tetanus-diphtheria vaccine in April 2025, using trehalose to stabilize it without refrigeration. The vaccine remained stable for 24 months at up to 30°C, but further studies are needed before it can be used in African immunisation programmes.HindustantimesFridge-free vaccines could reach more people, but there are still practical challenges in African settingsStablepharma began the first human trial of a fridge-free tetanus-diphtheria vaccine in April 2025, using trehalose to stabilize the vaccine without refrigeration. The vaccine remained stable for at least 24 months at up to 30°C, but further studies are needed before it can be used in African immunisation programmes.MedicalxpressFridge‑free vaccines could reach more people, but there are still practical challenges in African settingsStablepharma began the first human trial of a fridge-free tetanus-diphtheria vaccine in April 2025, using trehalose to stabilize the vaccine without refrigeration. The trial showed the vaccine was well tolerated and generated excellent immune responses, but further studies are needed before it can be used in African immunization programs.EIN PresswireTIME Names Stablepharma's Fridge-Free Vaccine a Best Invention of 2026Stablepharma's tetanus-diphtheria vaccine SPVX02 was named one of TIME's Best Inventions of 2026. The vaccine remains stable at 30°C for four years without refrigeration, and the company has initiated its pivotal Phase 2b trial. The technology aims to simplify vaccine logistics and improve access to temperature-sensitive medicines.Healthcare TodayÖzgür Tuncer: Health and vaccine equityStablePharma's CEO Özgür Tuncer discussed its thermostabilized tetanus-diphtheria vaccine SPVX02, which performed well in Phase 1 trials after 12 months at 30°C. He cited up to 50% global vaccine wastage from cold-chain failures and expects Phase 2b results in Q1 next year. The technology could reduce costs and improve vaccine equity.TechRound6 Startups Crowdfunding w/c 07.09.2026Six startups are crowdfunding this week, including Candam Technologies raising €300,060 for acoustic-AI recycling, Camden Town WFC raising £50,002 for women's football, and Stablepharma, Jay & Joy, Evogro, and Aqua Glow. The startups target recycling, sports, pharmaceuticals, plant-based cheese, indoor plants, and collagen drinks.Science NewsNo refrigerator, no problem. This experimental vaccine doesn’t need it.Researchers have developed an experimental tetanus and diphtheria vaccine, SPVX02, that remains effective without refrigeration for up to a year at 30°C due to a protective trehalose-based technology. Clinical trials involving 60 participants in the United Kingdom confirmed that the vaccine provides immunity comparable to standard refrigerated vaccines while avoiding significant side effects. The London-based company Stablepharma is now investigating whether this stabilization technique can be applied to other vaccines, such as those for hepatitis B and HPV.PharmaTimesFridge‑free vaccine shows global potentialA phase 1 trial of a fridge-free tetanus-diphtheria vaccine (SPVX02) showed all 60 participants achieved protective antibody levels by day 28 with no serious adverse events. The vaccine remained stable for two years at temperatures up to 30°C and after extreme fluctuations. A phase 2b trial is now underway to evaluate it in a larger population.SemaforFridge-free vaccines could prompt Africa immunization breakthroughResearchers have successfully trialed vaccines that can be stored without refrigeration, potentially transforming immunization efforts in Africa. The new technology, developed by Stablepharma, turns vaccines into a powder using trehalose, enabling room temperature storage and later reconstitution for injection.Manufacturing ChemistFridge-free tetanus-diphtheria vaccine passes first human trialSPVX02, a fridge-free tetanus-diphtheria vaccine, passed Phase I trials in 60 adults, showing protective antibody levels and no serious adverse events. It retains potency for at least two years at 30°C and six months at 40°C, with testing ongoing to extend stability to four years.